CRIS Current Research Information System

COLANGELI, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.254
AS - Asia 1.712
EU - Europa 1.212
AF - Africa 119
SA - Sud America 100
Continente sconosciuto - Info sul continente non disponibili 95
OC - Oceania 1
Totale 5.493
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.207
VN - Vietnam 476
SG - Singapore 461
CN - Cina 386
GB - Regno Unito 242
SE - Svezia 218
IT - Italia 203
DE - Germania 149
HK - Hong Kong 139
FR - Francia 92
IN - India 78
BR - Brasile 74
BD - Bangladesh 64
RU - Federazione Russa 64
IE - Irlanda 55
TG - Togo 51
UA - Ucraina 44
NL - Olanda 31
ZA - Sudafrica 27
FI - Finlandia 26
JO - Giordania 26
BG - Bulgaria 24
EE - Estonia 21
CI - Costa d'Avorio 18
CA - Canada 17
JP - Giappone 16
MX - Messico 13
TH - Thailandia 11
KR - Corea 10
PH - Filippine 10
AR - Argentina 8
NG - Nigeria 8
BE - Belgio 7
ID - Indonesia 7
PL - Polonia 7
TW - Taiwan 7
AT - Austria 6
CH - Svizzera 6
EC - Ecuador 6
SC - Seychelles 4
AO - Angola 3
CL - Cile 3
CO - Colombia 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
ES - Italia 3
EU - Europa 3
GR - Grecia 3
GT - Guatemala 3
PE - Perù 3
SA - Arabia Saudita 3
VE - Venezuela 3
CY - Cipro 2
IQ - Iraq 2
LT - Lituania 2
MY - Malesia 2
NI - Nicaragua 2
PA - Panama 2
PK - Pakistan 2
RO - Romania 2
RS - Serbia 2
TR - Turchia 2
AF - Afghanistan, Repubblica islamica di 1
AU - Australia 1
BF - Burkina Faso 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BZ - Belize 1
DK - Danimarca 1
DZ - Algeria 1
EG - Egitto 1
ET - Etiopia 1
GH - Ghana 1
HN - Honduras 1
IL - Israele 1
KE - Kenya 1
KN - Saint Kitts e Nevis 1
KY - Cayman, isole 1
LB - Libano 1
MS - Montserrat 1
NP - Nepal 1
OM - Oman 1
SI - Slovenia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
ZM - Zambia 1
Totale 5.401
Salva come PNG Salva come JPEG
Città #
Singapore 326
Ashburn 289
Southend 210
Fairfield 183
Chandler 162
San Jose 136
Santa Clara 134
Hong Kong 127
Woodbridge 104
Seattle 101
Hanoi 96
Ho Chi Minh City 93
Houston 90
Wilmington 69
Princeton 63
Cambridge 58
Beijing 56
Dublin 55
Dong Ket 52
Bologna 51
Lomé 51
Ann Arbor 47
Boardman 43
Council Bluffs 38
Los Angeles 31
Lauterbourg 30
Nanjing 30
Amman 26
Florence 26
Westminster 26
Berlin 24
New York 24
Sofia 24
Padova 20
Abidjan 18
Jacksonville 18
Buffalo 17
Rome 17
Milan 16
São Paulo 16
Jinan 15
Guangzhou 14
Hefei 14
Saint Petersburg 14
Da Nang 13
Hebei 13
Helsinki 13
Redondo Beach 13
San Diego 13
Tokyo 13
Turin 13
Changsha 12
Chicago 12
Dearborn 12
Haiphong 12
Redmond 12
Dallas 11
Nuremberg 11
Frankfurt am Main 10
Turku 10
Des Moines 9
Olalla 9
Shenyang 9
Abeokuta 8
Shanghai 8
The Dalles 8
Thái Nguyên 8
Zhengzhou 8
Nanchang 7
Ningbo 7
Phoenix 7
Tianjin 7
Bremen 6
Brooklyn 6
Brussels 6
Montreal 6
Shenzhen 6
Shijiazhuang 6
Bern 5
Bühl 5
Chennai 5
Düsseldorf 5
Falls Church 5
Hangzhou 5
Jiaxing 5
Johannesburg 5
Lanzhou 5
Munich 5
Taizhou 5
Warsaw 5
Yubileyny 5
Atlanta 4
Bangkok 4
Bến Tre 4
Hải Dương 4
Louisville 4
Ninh Bình 4
Orem 4
Quận Bình Thạnh 4
Toronto 4
Totale 3.479
Salva come PNG Salva come JPEG
Nome #
Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy 213
Calcaneal quantitative ultrasound (QUS) and dual X-ray absorptiometry (DXA) bone analysis in adult HIV-positive patients. 205
Dual raltegravir-darunavir/ritonavir combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy including a ritonavir-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors 197
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 191
Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study. 188
Plasma Levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. 186
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection. 185
Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitors: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mmc) 184
HIV-1 early and late diagnosis in the Emilia Romagna Region (Italy): A three year study 184
A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues 183
Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection. 183
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control study. 179
Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. 178
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. 173
Two-Year Treatment with Rosuvastatin Reduces Carotid Intima-Media Thickness in HIV Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy with Asymptomatic Atherosclerosis and Moderate Cardiovascular Risk. 172
No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy 171
Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS 169
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. 168
Abacavir-lamivudina versus tenofovir-emtricitabina più atazanavir-ritonavir nella semplificazione dell'HAART per dislipidemia 167
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients 162
Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. 158
Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy 156
No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up 153
Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemia 148
Prevalence of transmitted drug resistance mutations among newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy 148
Raltegravir use prospectically assessed in a major HIV outpatient clinic in Italy: sample population, virological-immunological activity, and tolerability profile 142
Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients 128
Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir 127
Integration among hospital pharmacists and infectious diseases physicians in the outpatient management of HIV infection 126
COVID-19 Outcomes in Patients With Uncontrolled HIV-1 Infection. 120
null 113
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir 103
Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain. 100
Efficacy and Safety of Dolutegravir/Lamivudine in Antiretroviral Therapy-Naive People Living With HIV-1 and With High-Level Viremia. 78
Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience. 55
Totale 5.493
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.526
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.526
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022595 0 27 35 79 66 26 12 29 21 114 108 78
2022/2023694 51 102 23 94 44 44 11 62 148 19 67 29
2023/2024211 14 31 9 33 10 52 8 21 7 11 9 6
2024/2025724 33 70 57 69 173 35 29 17 5 45 20 171
2025/20261.797 166 108 118 108 190 88 202 76 429 143 108 61
2026/202799 52 47 0 0 0 0 0 0 0 0 0 0
Totale 5.493